Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Kentucky Opioid Abatement Advisory Commission to Hear Personal Testimonies Supporting $42 Million Funding for Ibogaine Research


News provided by

Integration Communications

Sep 13, 2023, 09:40 ET

Share this article

Share toX

Share this article

Share toX

Ibogaine is a naturally occurring compound being explored as a treatment for opioid use disorder.
Ibogaine is a naturally occurring compound being explored as a treatment for opioid use disorder.

September 15 hearing will feature personal stories from parents, veterans, and others who have used ibogaine to treat Opioid Use Disorder

FRANKFORT, Ky., Sept. 13, 2023 /PRNewswire-PRWeb/ -- W. Bryan Hubbard, Chair and Executive Director of the Kentucky Opioid Abatement Advisory Commission (KYOAAC), along with members of the Commission, will hold a public hearing and general information session on Friday, September 15, 2023, highlighting the personal stories of parents, military veterans, former patients, psychologists, and others with perspectives on treating Opioid Use Disorder with the naturally occurring substance, ibogaine.

Friday's hearing will be the second of two public hearings as the Commission considers a landmark proposal to allocate $42 million over six years towards research into the treatment of Opioid Use Disorder with ibogaine-assisted therapy. The prior hearing, which took place on July 17, featured scientific experts and clinicians. The Commission will vote to decide whether to allocate the funding on November 15.

Observational data suggests that ibogaine could be added to the existing treatment options that we have, and that it may represent a breakthrough opportunity to pioneer an additional therapeutic. - W. Bryan Hubbard, Chair of KYOAAC

Post this

If approved, the funds will be dispensed from the state's share of the $842 million in settlements with opioid manufacturers and distributors for their role in exacerbating the deadly opioid crisis. KYOAAC is responsible for distributing half of the settlement funds, or $421 million. The funds are to be distributed for the delivery of interventional, therapeutic, and recovery services for individuals, families, and communities which have been ravaged by the state's opioid addiction epidemic.

The Commission will be joined by a panel of former sufferers of opioid addiction and their families. Panelists will share their personal experiences with ibogaine and opioids with members of the Commission and the general public in order to provide much-needed context into the impact that the proposed research may have on addiction sufferers and their families.

Credentialed media interested in watching the public hearing may attend in person at the address below, or watch the livestream on September 15.

WHO:

  • W. Bryan Hubbard (Chairman and Executive Director, KYOAAC)
  • Ben Chandler (former Attorney General of Kentucky, former five-term Congressman, president and CEO of Foundation for a Healthy KY)
  • Jerry Catlett (father of ibogaine therapy patient)
  • Paria Zandi (licensed therapist)
  • Bobby Laughlin (CEO in private equity)
  • Dr. Joseph Barsuglia (clinical and research psychologist)
  • Tommy Aceto (ibogaine patient and U.S. Navy SEAL veteran)
  • Ryan Roberts (ibogaine patient and U.S. Marine Corps veteran)
  • Dr. Andrew Tatarsky (psychologist and developer of Integrative Harm Reduction Therapy)
  • Marcus Capone (U.S. Navy SEAL veteran and co-founder of Veterans Exploring Treatment Solutions)
  • Amber Capone (Executive Director of Veterans Exploring Treatment Solutions)
  • Susan Ousterman (mother and founder of Vilomah Memorial Foundation)
  • Reed Madison (father of ibogaine therapy patient)
  • Angela Hargrove (wife of ibogaine therapy patient, Senior Director of Elligo Health Research)
  • Nico Avante (ibogaine therapy patient, father of ibogaine patient, and founder of Avante Institute)
  • Steve Viola (U.S. Navy SEAL veteran and Executive Director of Mission Within)
  • Talia Eisenberg (former opioid user and co-founder of Beond)
  • Adam Marr (retired Army Apache pilot and Director of Operations for Veteran Mental Health Leadership Coalition)
  • Michael Higgs (parent and U.S. Navy SEAL veteran)
  • Lt. Gen. Martin R. Steele (U.S. Marine Corps veteran)

WHAT:

Public hearing and general information session

WHEN:

Friday, September 15, 2023, from 9 AM - 3:30 PM EDT

WHERE:

Administrative Office of the Courts Building
Room A125
1001 Vandalay Dr.
Frankfort, KY 40601

Or watch the public livestream here.

Media Contact

Brad Burge, Integration Communications, 1 6508636887, [email protected]

SOURCE Integration Communications

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.